Tamoxifen 40 - Stealth Labs

Tamoxifen citrate began its development in 1962 under ICI as a potential female contraceptive. When it proved ineffective in that role, researchers recognized its ability to block estrogen activity selectively, especially in breast tissue. Its transition to cancer therapy led to FDA approval in 1977 under the name Nolvadex. It soon became the most widely prescribed SERM in oncology. In later years, its utility extended into sports pharmacology as a tool for managing estrogen-related effects from anabolic steroid use.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Tamoxifen 40 by Stealth Labs, consult with your doctor or healthcare professional.